Omicsgen Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.90 M
as on 17-07-2024
- Paid Up Capital ₹ 0.90 M
as on 17-07-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 67.62%
(FY 2022)
- Profit 419.58%
(FY 2022)
- Ebitda 820.66%
(FY 2022)
- Net Worth 753.08%
(FY 2022)
- Total Assets 129.43%
(FY 2022)
About Omicsgen Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.90 M and a paid-up capital of Rs 0.90 M, as per Ministry of Corporate Affairs (MCA) records.
Puthuvayankunnath Beena, Santhosh Vilas, and Aardhra Santhosh serve as directors at the Company.
- CIN/LLPIN
U74999KL2017PTC050248
- Company No.
050248
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Aug 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Kanayannur, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Omicsgen Lifesciences Private Limited offer?
Omicsgen Lifesciences Private Limited offers a wide range of products and services, including Hand Sanitizers & Personal Hygiene, Air Fresheners, Cleaning Liquids & Wipes, Surface Cleaner, Disinfectant Spray.
Who are the key members and board of directors at Omicsgen Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santhosh Vilas  | Director | 16-Jan-2018 | Current |
| Puthuvayankunnath Beena | Director | 29-Aug-2017 | Current |
| Aardhra Santhosh | Director | 15-Jan-2020 | Current |
Financial Performance of Omicsgen Lifesciences.
Omicsgen Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 67.62% increase. The company also saw a substantial improvement in profitability, with a 419.58% increase in profit. The company's net worth Soared by an impressive increase of 753.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Omicsgen Lifesciences?
In 2022, Omicsgen Lifesciences had a promoter holding of 81.00% and a public holding of 19.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Omicsgen Lifesciences?
Unlock and access historical data on people associated with Omicsgen Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Omicsgen Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Omicsgen Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
